WO1997028181A2 - Post-labeling stabilization of radiolabeled proteins and peptides - Google Patents
Post-labeling stabilization of radiolabeled proteins and peptides Download PDFInfo
- Publication number
- WO1997028181A2 WO1997028181A2 PCT/US1997/001695 US9701695W WO9728181A2 WO 1997028181 A2 WO1997028181 A2 WO 1997028181A2 US 9701695 W US9701695 W US 9701695W WO 9728181 A2 WO9728181 A2 WO 9728181A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- radiolabeled
- protein
- peptide
- ascorbic acid
- stabilizer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
Definitions
- This invention relates to stabilizers for radiopharmaceutical compositions which are added after radiolabeling but prior to admimstration.
- Ascorbic acid and/or a derivative thereof, alone or in combination with other stabilizers, is used to inhibit oxidation loss and autoradiolysis of radiolabeled peptides and proteins.
- Protein- or peptide-based radiopharmaceuticals are primarily based upon use of monoclonal antibodies (or fragments thereof) as a targeting vehicle, but other peptides or proteins can also be used, including albumins and hormones. Both intact antibodies (monoclonal and polyclonal) and fragments, made by any method known to the art, as well as peptide mimics of fragments or antibody binding sites can be radiolabeled and used as imaging, diagnostic or therapeutic agents.
- Radiolabeled peptide analogues of somatostatin used for diagnostic imaging include 123 I-labeled Tyr-3-octreotide and n, In-diethylene tetraaminepentaacetic acid (DTPA)-octreotide imaging agents.
- DTPA In-diethylene tetraaminepentaacetic acid
- Both protein- and peptide-based radiopharmaceuticals may be radiolabeled by a variety of means. Both peptides and proteins can be directly radioiodinated, through electrophilic substitution at reactive aromatic amino acids. Iodination may also be accomplished via prelabeled reagents, in which the reagent is iodinated and purified, and then linked to the peptide or protein.
- the utility of DTPA and EDTA chelates covalently coupled to proteins, polypeptides and peptides is well known in the art.
- DTPA has been used as a bifiinctional chelating agent for radiolabeling a variety of peptides with m In, including somatostatin analogues for cancer imaging, ⁇ -melanocyte-simulating hormone for imaging melanoma, chemotactic peptides for infection imaging, laminin fragments for targeting tumor-associated laminin receptors and atrial natriuretic peptides for imaging atrial natriuretic receptors in the kidney.
- Tc is a preferred isotope for diagnostic imaging, due to its low cost, ready availability, excellent imaging properties and high specific activities.
- Two approaches have been described for radiolabeling proteins and peptides with ""Tc: direct labeling and bifiinctional chelates.
- Direct labeling methods are generally described in U.S. Patents 5,078,985; 5,102,990; 5,277,893; 5,443,816; and 5,460,785 referenced above, in which a variety of methods of direct labeling of peptides and proteins through sulfur-, oxygen- and nitrogen-containing amino acid sequences available for binding are disclosed.
- a variety of high affinity chelates to bind Tc to specific sites on peptides have been developed.
- the bifiinctional reagent is first labeled with ""Tc, and then conjugated to the peptide.
- a chelating agent is covalently attached to the peptide prior to radiolabeling.
- Chelates which have been employed include a variety of N2S2 and N3S ligands, DTPA, 6-hydrazinonicotinate groups, metallothionein and metallothionein fragments.
- Isotopes of rhenium principally ,86 Re and 188 Re, have been used to radiolabel proteins and peptides for investigation as therapeutic agents.
- the chemistry of 1M Re and I88 Re is similar to that of ""Tc, though not identical, and both direct and chelate labeling approaches have been used in radiolabeling proteins and peptides with rhenium.
- Radiopharmaceutical compositions are known to degrade after radiolabeling, primarily by oxidation losses and by autoradiolysis. Some radiopharmaceuticals, such as Tc, and especially 186 Re and 188 Re labeled compounds, are particularly susceptible to oxidation losses if the isotope is not maintained in a suitable oxidation state. Both technetium and rhenium isotopes normally exist in their highest or +1 oxidation state, which is the stable state, until reduced with stannous or other reducing agents.
- a technetium or rhenium radiolabeled compound can become unstable if the complexed reduced isotope is oxidized to a higher oxidation state, releasing the bound isotope as free or unbound pertechnetate +7 or free perrhenate +7.
- Autoradiolysis includes chemical decomposition of a radiolabeled peptide or protein by the action of radiation emitted from the radioisotope coupled to the peptide or protein. Autoradiolysis may be caused by the formation of free radicals in the water or other medium due to the effect of radiation emitted from the radioisotope. Free radicals are molecules or atoms containing a single unpaired electron, which exhibit high chemical reactivity. Autoradiolysis is a significant problem with high energy Remitting isotopes, such as rhenium isotopes, and with ⁇ -emitting isotopes, but is typically somewhat less of a problem with ⁇ -emitting isotopes, such as ""Tc.
- Patent 5,384,113 incorporated herein by reference, and use of ascorbic acid to stabilize some chemical-based radiolabeled compounds, but not protein- or peptide-based radiolabeled compounds, is described in Tofe, AJ. and Francis, M.D., J. Nucl. Med., 17, 820-825
- a composition containing a radiolabeled protein or peptide having improved stability e.g., against oxidation, autoradiolysis and more generally degradation.
- Another object is to provide novel methods for stabilizing a radiolabeled protein peptide or polypeptide.
- the present invention provides a method for stabilizing radiopharmaceutical compositions, including compositions based on peptides and proteins, including antibodies.
- the method comprises adding ascorbate or other stabilizing agents to the pre-radiolabeled composition in an amount effective to prevent degradation of the radiolabeled substance, such as that caused by autoradiolysis of the labeled composition and oxidation loss of the radiolabel.
- a method of preparing a stabilized peptide or protein radiopharmaceutical composition comprising the ordered steps of labeling a peptide or protein with a radioisotope to form a radiolabeled pharmaceutical product, said radiolabeled pharmaceutical product being substantially free of any stabilizing agents, and then adding a stabilizing agent consisting of ascorbic acid, or one or more derivatives thereof (such as salts, esters, and mixtures thereof) to the radiolabeled pharmaceutical product.
- the radioisotope may be an isotope of rhenium or technetium, and particularly ""Tc, 186 Re or 188 Re.
- a method of preparing a stabilized rhenium-labeled peptide-based somatostatin analogue radiopharmaceutical composition comprising the ordered steps of labeling said peptide with an isotope of rhenium to form a radiolabeled pharmaceutical product, said radiolabeled pharmaceutical product being heretofore substantially free of any stabilizing agents, and then adding a stabilizing agent consisting of ascorbic acid, its salts, esters, derivatives and mixtures thereof to the radiolabeled pharmaceutical product.
- the radioisotope may be 186 Re or 188 Re.
- a method of preparing a stabilized technetium-labeled anti-SSEA-1 IgM antibody-based radiopharmaceutical composition comprising the ordered steps of labeling said anti-SSEA-1 antibody with an isotope of technetium to form a radiolabeled pharmaceutical product, said radiolabeled pharmaceutical product being heretofore substantially free of any stabilizing agents, and then adding a stabilizing agent consisting of ascorbic acid, its salts, esters, derivatives and mixtures thereof to the radiolabeled pharmaceutical product.
- the radioisotope may be ""Tc.
- the present invention provides stabilized compositions containing a radiolabeled protein or peptide, which compositions have been stabilized by the addition of a stabilizing agent containing ascorbic acid or a derivative thereof to a composition containing said protein or peptide already radiolabeled.
- FIGURE 1 Elution profile of Re-188-RC-160 labeled with 65 mCi of Re-188 at 6 hours post-labeling from a C 18 -reverse-phase HPLC column.
- the y-axis in arbitrary units.
- the figure inset is an elution profile of Re-188-RC- 160 from a C, g -SepPak column using a step-gradient of acidified ethanol.
- FIGURE 2 Comparative elutions profiles of Re-188-RC-160 radiolabeled at either 90°C or 37°C.
- FIGURE 3 Displacement of Re-188 from Re-188-RC-160 using increasing concentrations of cysteine as a challenge agent.
- FIGURE 4 Comparative biodistribution of Re-188-RC-160 radiolabeled at either 90°C or 37°C in normal female mice.
- FIGURE 5 Comparison of Tc-99m- or Re-188- labeled RC-160 over time as analyzed by TLC. Saline was used as a mobile phase. Similar amounts (20 mCi) of each radionuclide were used, and the same formulation (optimized for Re-labeling) was used in the comparison. No post- labeling stabilizer was used.
- FIGURE 6 Comparative TLC of Re-188-RC-160 with and without post-labeling stabilization with ascorbate.
- HGURE 7 Elution profile of Re-188-RC-160 labeled with 65 mCi of Re-188 at 30 hours post-labeling from a C -reverse-phase HPLC column. The y-axis in arbitrary units.
- HGURE 8 Comparative elution profiles of Re-188-RC-160 with ascorbate added after the radiolabeling (top) or before the radiolabeling (bottom). Both preparations were radiolabeled with 10 mCi (370 Mbq) of Re-188.
- HGURE 9 Labeling of a RhoMed radiophamaceutical produ . known as LeuTec- MTM, a ""Tc-labeled anti-SSEA- 1 antibody. (This product is referred to as "Leuko- 1" in Figure 9, which is a summary of the test results from a lot of LeuTecMTM manufactured by RhoMed.) This data shows the difference in radiolabeling yields between unstabilized and stabilized (with ascorbate) product.
- HGURE 10 HPLC profile on Tc-labeled IgM samples showing the difference in yield over time with labeling occurring in the presence of ascorbate or with postlabeling addition of ascorbate.
- the present invention is directed to radiolabeled protein- or peptide-containing compositions with a stabilizing agent added subsequent to radiolabeling but prior to use to prevent oxidation and autoradiolysis.
- a stabilizing agent which is effective at preventing oxidation and autoradiolysis is ascorbic acid (and derivatives thereof).
- ascorbic acid and its derivatives interfere with radiolabeling if included in the composition prior to or during radiolabeling.
- the inventors have found that, unexpectedly, when added subsequent to radiolabeling (and subsequent to any incubation period), ascorbic acid and its derivatives result in a radiolabeled substance of superior stability and body (volume).
- radiolabeled proteins and peptides which are effectively stabilized according to the present invention include radiopharmaceutical drugs having diagnostic or therapeutic applications. While the methods of this invention are particularly applicable to stabilizing compositions including isotopes of technetium and rhenium, such as ""Tc,
- compositions including a wide variety of isotopes including those found in the group consisting of elements 26-30 (Fe, Co, Ni, Cu, Zn), 33-34 (As, Se), 42-50 (Mo, Tc, Ru, Rh, Pd, Ag, Cd, In, Sn) and 75-85 (Re, Os, Ir, Pt, Au, Hg, Tl, Pb, Bi, Po, At) of the group consisting of elements 26-30 (Fe, Co, Ni, Cu, Zn), 33-34 (As, Se), 42-50 (Mo, Tc, Ru, Rh, Pd, Ag, Cd, In, Sn) and 75-85 (Re, Os, Ir, Pt, Au, Hg, Tl, Pb, Bi, Po, At) of the group consisting of elements 26-30 (Fe, Co, Ni, Cu, Zn), 33-34 (As, Se), 42-50 (Mo, Tc, Ru, Rh, Pd, Ag, Cd, In, Sn) and
- Radioisotopes with diagnostic or therapeutic applications include 62Cu, 64Cu, 67Cu, 97Ru, 105Rh, 109Pd, ,86 Re, l88 Re, 198Au, 199Au, 203Pb, 211Pb and 212Bi.
- radiolabeled peptide compositions stabilized by means of this invention include proteins, peptides and polypeptides which are naturally-occurring, as well as those produced by chemical synthesis, by recombinant DNA technology, by biochemical or enzymatic fragmentation of larger molecules, or by any other means for producing them.
- peptides stabilized by the present method include peptide fragments, polypeptides and other structures derived therefrom, generally consisting of a sequence of amino acids.
- peptides include those derived from laminin, fibronectin, cytokines, lymphokines, serum albumin, fibrinogen, enzymes, hormones, somatostatin, urokinase, tissue plasminogen activator, and protease inhibitors.
- Peptides will generally comprise fewer than 100 amino acids, and preferably fewer than 60 amino acids, and most preferably comprise between about 4 and about 20 amino acids.
- amino acids forming all or a part of the peptide may be naturally occurring amino acids, isomers and modifications of such amino acids, non-protein amino acids, post-translationally modified amino acids, enzymatically synthesized amino acids, isosteric amino acid analogues and the like, so that the term “peptide” includes pseudopeptides and peptidomimetics.
- peptide also includes cyclic peptides, bridged peptides (e.g. , disulfide-bridged peptides), dimers or multimers of peptides.
- Radiolabeled protein compositions stabilized by means of this invention include such proteins, whether natural or synthetic, as human serum albumin, fibrinogen, urokinase, gamma globulin, laminin, fibronectin, cytokines, lymphokines, enzymes, enzyme inhibitors, hormones, glycoproteins, and immunoglobulins.
- the term "protein” as used throughout the specification and claims is intended to include all of the foregoing substances.
- the protein is typically of mammalian origin, but also includes proteins of plant origin and proteins from prokaryotic cells. Methods of attaching or complexing proteins to other molecules, such as lipids and carbohydrates, including liposomes, are known to those skilled in the art.
- Immunoglobulins include antibodies and antibody fragments (including fragments consisting essentially of an antigenic determinant or antigen binding site), of any species, and include both polyclonal and monoclonal antibodies made by any means, as well as chimeric and genetically engineered antibodies, hybrids, and fragments of all of the foregoing.
- immunoglobulins of any class such as IgG, IgM, IgA, IgD or IgE, of any species origin, including human beings, chimeric antibodies or hybrid antibodies with dual or multiple antigen or epitope specificities, and fragments of all of the foregoing, including F(ab)2, F(ab)2, Fab, Fab and other fragments, including hybrid fragments, and further includes any immunoglobulin or any natural, synthetic or genetically engineered protein that functionally acts like an antibody by binding specifically to a given antigen to form a complex, including single chain antibodies.
- antibody or “antibodies” as used throughout the specification and claims are intended to include all such antibodies and antibody fragments.
- the products stabilized by means of the invention set forth herein can be used for both medical applications and veterinary applications. Typically, the product is used in humans, but may also be used in other mammals.
- the term "patient” is intended to include a mammal, and is so used throughout the specification and in the claims.
- the primary applications of the invention involve human patients, but the invention may be applied to laboratory, farm, zoo, wildlife, pet or sport animals.
- the products stabilized by means of the invention set forth herein can be used as imaging agents, for example, to view tissues in order to monitor normal or abnormal metabolic events, to localize normal or abnormal tissues, to localize diseases, to diagnose or treat diseases, and to bind to blood constituents, including blood cells, such as lymphocytes, for subsequent localization of diseases, infections, and abnormal tissues.
- imaging agents for example, to view tissues in order to monitor normal or abnormal metabolic events, to localize normal or abnormal tissues, to localize diseases, to diagnose or treat diseases, and to bind to blood constituents, including blood cells, such as lymphocytes, for subsequent localization of diseases, infections, and abnormal tissues.
- the application and medical use of the product depends on the type of protein or peptide and the type of radioisotope. used.
- the protein or peptide is first labeled with a radioisotope which can be accomplished using known techniques, and once labeling is complete, it is then stabilized according to the invention.
- the radioisotope may generate gamma rays, beta particles, or positrons which are converted into gamma rays upon collision with electrons.
- the radioisotope may be used in diagnostic imaging procedures including gamma scintigraphy, specific photon emission computerized tomography, or positron emission tomography, or may be used therapeutically.
- the addition of ascorbic acid to achieve concentrations between about 0.001 wt% and 5 wt% to the composition post-labeling increases the stability of the radiolabeled composition, with apparent increased resistance to oxidation and/or radiolytic decomposition. If excess stannous or stannic ions are present in the composition of the labeled peptide or protein, the addition of ascorbic acid also prevents formation of Sn-colloids and other radiochemical impurities.
- compositions in which ascorbic acid has been present prior to completion of radiolabeling
- the stabilizing agent ascorbic acid or a derivative thereof
- the stabilizing agent be added to the composition containing a radiolabeled peptide or protein only after radiolabeling is complete (i.e. , after the label has been attached to the peptide or protein and any incubation period has elapsed).
- antioxidants notably ascorbic acid (and derivatives thereof)
- antioxidants inhibit radiolysis and free radical damage to proteins or peptides labeled with isotopes emitting high energy photons or particles, such as the 2 MeV beta particle emitted upon decay of 188 Re.
- Free radical degradation in particular can be significant, and generally increases with both time and incre sed amounts of radioactivity in the preparation.
- ascorbic acid or derivative has the added advantage in a pharmaceutical or clinical setting for the purpose of "bulking" the preparation, that is, giving the preparation a certain required minimum volume for easy manipulation and use.
- preparations of ascorbic acid (or derivative) for injection are commercially available, and exhibit little or no toxicity. If not available, they can be synthesized using known techniques.
- a protein or peptide radiolabeling kit may be employed, which will contain one or more vials containing the protein or peptide to be radiolabeled, and may contain a transfer ligand, a reducing agent, depending on the radioisotope to be employed, other radiolabeling reagents and one or more excipients.
- the contents of a vial may be lyophilized, frozen or in liquid formulation.
- the radioisotope typically in an aqueous solution, is added to the vial containing the protein or peptide to be radiolabeled to initiate radiolabeling. It is key that the radiolabeling vial not include ascorbic acid or derivative since their presence may adversely affect radiolabeling.
- ascorbic acid and other stabilizing agents are conventionally included in the radiolabeling kit in a separate vial, or may be obtained from other sources in a separate vial.
- the radiolabeling vial is allowed to incubate for a period of time, generally ranging from 15 minutes to one hour, at a temperature ranging from room temperature to 100°C. After the incubation period is completed, unreacted label and/or excess reducing agent are optionally removed, the ascorbic acid or derivative thereof then added to the radiolabeled protein or peptide in the radiolabeling vial.
- compositions containing ascorbic acid may be used, typically containing 500 mg/2 ml ascorbic acid, with the volume added ranging from 10 ⁇ l to 2 ml, and preferably from 250 ⁇ to 1 ml.
- the derivative may be a physiologically acceptable water soluble salt of ascorbic acid, such as sodium ascorbate, potassium ascorbate, lithium ascorbate, etc. or ester of ascorbic acid.
- an equivalent amount is used.
- the composition may be prepared for administration.
- the radiolabeled composition is administered parenterally, and most commonly intravenously, but other forms of administration are contemplated and possible.
- the stabilizer of the invention is added as soon as radiolabeling is complete. If any purification of the radiolabeled protein is necessary, the stabilizer can be added after such purification. It is an advantage of the invention, however, that incorporation of the stabilizer in compositions containing excess stannous ion prevents formation of quantities of stannous colloids and other radiochemical impurities that would interfere with performance of the radiolabeled protein or peptide for its intended imaging diagnostic or therapeutic purpose.
- RC-160 is a cyclic somatostatin analogue with the general structure:
- Radiolabeling kits were prepared using aseptic techniques, with each kit prepared in a 10 ml serum vial using a 2 ml liquid fill.
- the liquid fill contained 200 ⁇ g of RC-160 peptide in 45 mM sodium potassium tartrate, 10 mM potassium hydrogen phthalate buffer, pH 5.0, in 5 mM stannous tartrate with 1 % maltose added as a freeze-drying excipient.
- Each kit contained a maximum of 1 ⁇ 9 ⁇ g of tin. After filling, the vials were lyophilized, the head space gas filled with nitrogen, and the vials stoppered and crimped. Lyophilized vials were then stored refrigerated at 2-8°C.
- a kit 4-5 ml of 188 Re-perrhenate solution containing 10-100 mCi was added to the kits, and the kits then heated in a boiling water bath for 30-45 minutes. Following a brief cooling period, 2 ml of ascorbic acid for Injection, U.S.P., was added to the labeled kit through a 0.22 micron filter. Two types of parenteral ascorbate were used with similar results, Ascorbic Acid for Injection, U.S.P., 500 mg/2 ml, and AscorvitTM (a preparation of ascorbate) 100 mg (Jenapharm, Germany). An elution profile from an analytical HPLC at 6-hours post-labeling is shown in Fig. 1.
- RC-160 was radiolabeled at pH 5.0 for 30 minutes at 90°C and ascorbate was added post- labeling.
- the temperature effect is shown in Fig. 2: 19 minutes for 37°C and 21 minutes for 90°C.
- Fig. 1 is an elution profile of Re-188-RC
- RP-HPLC revealed an elution profile indicative of inefficient radiolabeling in the presence of this low amount of ascorbic acid.
- the RP-HPLC results were confirmed by TLC.
- the radiolabeling kit could be formulated with an excess of stannous ions and RC-160 to accommodate a variety of labeling situations. In the presence of .
- 188 Re the RC-160 and stannous ions interact to result in what is believed to be metal-cyclized 188 Re-RC-160.
- T he 18 *Re-RC-160 was demonstrated by RP-HPLC not to be identical with stannous-ion-reduced RC-160, or RC-160 reduced with dithiothreitol. Since 188 Re is produced essentially carrier-free from a 188W/ 188 Re generator, it is hypothesized that excess stannous ions will reduce the RC-160 not complexed to 188 Re.
- each vial was radiolabeled by the addition of "Tc sodium pertechnetate in a volume of 1.0 ml saline, followed by incubation for 30 minutes at 37°C. The radiolabeled antibody was then evaluated.
- each vial was radiolabeled by the addition of
- the net immunoreactive fraction was 51 % when ascorbic acid stabilizing agent was added, and 46% when it was not added. In another lot of kits, the net immunoreactive fraction was 59% when ascorbic acid stabilizing agent was added, and 42% when it was not added.
- a radiolabeling kit was formulated which included a 3 ml reaction vial containing the following lyophilized components:
- the formulation pH is adjusted to 6.2 ⁇ 0.1 with NaOH and/or HCl prior to dispensing 0.50 ml per vial and lyophilizing.
- the product contains no bacteriostatic preservative.
- Minimum stannous tin is 10 micrograms and total tin is 24 micrograms.
- One 2 ml ampule of commercially available Ascorbic Acid Inject ion, U.S. P. (Ascorbic Acid 250 mg/ml and Edetate Disodium 0.025 % in water for injection) is included in the radiolabeling kit.
- Ascorbic Acid solution (0.75 ml) is added after ""Tc labeling as a stabilizer for the reconstituted product.
- the 3 ml reaction vial with lyophilized components is removed from 2 -8°C storage and allowed to come to room temperature. Without the addition of air, the contents of the vial are aseptically reconstituted with up to 40 mCi (1500 MBq) of Sodium Pertechnetate ""Tc Injection (0.25 ml) from a fresh generator elution. The vial is gently swirled until the lyophilized product is completely dissolved. The reaction vial containing Sodium Pertechnetate ""Tc Injection is incubated for 30 minutes at 37°C.
- kits were prepared as in Example 3, except that one kit contained a total of 18 g of stannous tartrate, another kit contained a total of 24 g of stannous tartrate, and a third kit contained a total 30 g of stannous tartrate.
- Each kit was labeled with 20 mCi of ""Tc sodium pertechnetate in a volume of 250 ⁇ l, with incubation for 30 minutes at 37°C. Following incubation, 50 ⁇ l of each radiolabeled preparation was removed, to which was added 150 ⁇ l of an ascorbic acid solution. Each of the resulting six different preparations was tested for immunoreactivity as described in Example 2.
- kits were formulated using polyclonal human gamma globulin as the protein to be radiolabeled.
- a variety of reducing agents including dithionite, sulfite, and tetrathionate were employed, wit h stannous used to reduce the ""Tc sodium pertechnetate.
- Each type of different kit was radiolabeled both with and without ascorbic acid in the radiolabeling solution, and in each case the presence of ascorbic acid during radiolabeling adversely affected labeling yields, blood levels obtained upon intravenous injection of the radiolabeled preparation into experimental animals, and the resistance of the labeled antibody to challenge with cysteine.
- FIG 10 shows HPLC profiles of ""Tc- labeled IgM samples, showing the difference in yield over time with labeling occurring in the presence of ascorbate on the one hand, and addition of ascorbate post-labeling on the other.
- the top panel illustrates results obtained with ascorbate (50 mg/ml, pH 6.G), sodium sulfite (1 mg/ml, pH 7.4) or sodium bisulfite (1 mg/ml, pH 5.5).
- the bottom panel illustrates results obtained with Ascorbate for Injection, USP, or the Ascorvit formulation.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002279349A CA2279349C (en) | 1996-02-02 | 1997-02-03 | Ascorbate-stabilized radiopharmaceutical method and composition |
AU25264/97A AU2526497A (en) | 1996-02-02 | 1997-02-03 | Post-labeling stabilization of radiolabeled proteins and peptides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1102796P | 1996-02-02 | 1996-02-02 | |
US60/011,027 | 1996-02-02 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1997028181A2 true WO1997028181A2 (en) | 1997-08-07 |
WO1997028181A3 WO1997028181A3 (en) | 1997-10-09 |
WO1997028181A9 WO1997028181A9 (en) | 1998-03-05 |
Family
ID=21748542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/001695 WO1997028181A2 (en) | 1996-02-02 | 1997-02-03 | Post-labeling stabilization of radiolabeled proteins and peptides |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2526497A (en) |
CA (1) | CA2279349C (en) |
WO (1) | WO1997028181A2 (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002004030A2 (en) * | 2000-07-06 | 2002-01-17 | Bristol-Myers Squibb Pharma Company | Stable radiopharmaceutical compositions |
WO2003000271A2 (en) * | 2001-06-22 | 2003-01-03 | The University Of Alberta, The University Of British Columbia, Carleton University, Simon Fraser University And The University Of Victoria, Collectively Doing Business As Triumf | System and method for the large scale labeling of compounds with radiohalogens |
EP1365813A2 (en) * | 2001-02-26 | 2003-12-03 | Bristol-Myers Squibb Pharma Company | Ascorbic acid analogs for metalloradiopharmaceuticals |
US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
US7919109B2 (en) | 1999-02-08 | 2011-04-05 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
JP2012516328A (en) * | 2009-01-30 | 2012-07-19 | ネオプローブ コーポレイション | Composition for radiolabeling diethylenetriaminepentaacetic acid (DTPA) -dextran |
US9572889B2 (en) | 2008-02-13 | 2017-02-21 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
US9682127B2 (en) | 2005-02-03 | 2017-06-20 | Intarcia Therapeutics, Inc. | Osmotic delivery device comprising an insulinotropic peptide and uses thereof |
US9724293B2 (en) | 2003-11-17 | 2017-08-08 | Intarcia Therapeutics, Inc. | Methods of manufacturing viscous liquid pharmaceutical formulations |
WO2017155937A1 (en) | 2016-03-07 | 2017-09-14 | Actinium Pharmaceuticals, Inc. | Stabilized radiolabeled anti-cd45 immunoglobulin compositions |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
USD835783S1 (en) | 2016-06-02 | 2018-12-11 | Intarcia Therapeutics, Inc. | Implant placement guide |
US10159714B2 (en) | 2011-02-16 | 2018-12-25 | Intarcia Therapeutics, Inc. | Compositions, devices and methods of use thereof for the treatment of cancers |
US10231923B2 (en) | 2009-09-28 | 2019-03-19 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
US10501517B2 (en) | 2016-05-16 | 2019-12-10 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
US10527170B2 (en) | 2006-08-09 | 2020-01-07 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies for use therein |
US10835580B2 (en) | 2017-01-03 | 2020-11-17 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
US10925639B2 (en) | 2015-06-03 | 2021-02-23 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
NZ572003A (en) | 2006-05-30 | 2010-07-30 | Intarcia Therapeutics Inc | Two-piece, internal-channel osmotic delivery system flow modulator with spiral fluid channel |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4401646A (en) * | 1981-05-08 | 1983-08-30 | University Patents Inc. | Method and apparatus for purifying materials radiolabeled with technetium-99m |
US4988496A (en) * | 1988-05-31 | 1991-01-29 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
US5308603A (en) * | 1990-03-27 | 1994-05-03 | Thomas Jefferson University | Method to directly radiolabel antibodies for diagnostic imaging and therapy |
US5384113A (en) * | 1991-08-29 | 1995-01-24 | Mallinckrodt Medical, Inc. | Stabilizers to prevent autoradiolysis of radiolabeled peptides and proteins |
US5405597A (en) * | 1991-09-10 | 1995-04-11 | Diatech, Inc. | Technetium-99m labeled somatostatin-derived peptides for imaging |
-
1997
- 1997-02-03 AU AU25264/97A patent/AU2526497A/en not_active Withdrawn
- 1997-02-03 CA CA002279349A patent/CA2279349C/en not_active Expired - Fee Related
- 1997-02-03 WO PCT/US1997/001695 patent/WO1997028181A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4401646A (en) * | 1981-05-08 | 1983-08-30 | University Patents Inc. | Method and apparatus for purifying materials radiolabeled with technetium-99m |
US4988496A (en) * | 1988-05-31 | 1991-01-29 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
US5308603A (en) * | 1990-03-27 | 1994-05-03 | Thomas Jefferson University | Method to directly radiolabel antibodies for diagnostic imaging and therapy |
US5384113A (en) * | 1991-08-29 | 1995-01-24 | Mallinckrodt Medical, Inc. | Stabilizers to prevent autoradiolysis of radiolabeled peptides and proteins |
US5405597A (en) * | 1991-09-10 | 1995-04-11 | Diatech, Inc. | Technetium-99m labeled somatostatin-derived peptides for imaging |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
US8048438B2 (en) | 1999-02-08 | 2011-11-01 | Intarcia Therapeutics, Inc. | Stable non- aqueous single phase viscous vehicles and formulations utilizing such vehicles |
US7919109B2 (en) | 1999-02-08 | 2011-04-05 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
WO2002004030A2 (en) * | 2000-07-06 | 2002-01-17 | Bristol-Myers Squibb Pharma Company | Stable radiopharmaceutical compositions |
WO2002004030A3 (en) * | 2000-07-06 | 2003-02-27 | Bristol Myers Squibb Pharma Co | Stable radiopharmaceutical compositions |
EP1365813A2 (en) * | 2001-02-26 | 2003-12-03 | Bristol-Myers Squibb Pharma Company | Ascorbic acid analogs for metalloradiopharmaceuticals |
EP1365813A4 (en) * | 2001-02-26 | 2006-03-22 | Bristol Myers Squibb Pharma Co | Ascorbic acid analogs for metalloradiopharmaceuticals |
WO2003000271A3 (en) * | 2001-06-22 | 2003-04-17 | Univ Alberta The University Of | System and method for the large scale labeling of compounds with radiohalogens |
US7238338B1 (en) | 2001-06-22 | 2007-07-03 | Triumf | System and method for the large scale labeling of compounds with radiohalogens |
WO2003000271A2 (en) * | 2001-06-22 | 2003-01-03 | The University Of Alberta, The University Of British Columbia, Carleton University, Simon Fraser University And The University Of Victoria, Collectively Doing Business As Triumf | System and method for the large scale labeling of compounds with radiohalogens |
US9724293B2 (en) | 2003-11-17 | 2017-08-08 | Intarcia Therapeutics, Inc. | Methods of manufacturing viscous liquid pharmaceutical formulations |
US10363287B2 (en) | 2005-02-03 | 2019-07-30 | Intarcia Therapeutics, Inc. | Method of manufacturing an osmotic delivery device |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
US9682127B2 (en) | 2005-02-03 | 2017-06-20 | Intarcia Therapeutics, Inc. | Osmotic delivery device comprising an insulinotropic peptide and uses thereof |
US10527170B2 (en) | 2006-08-09 | 2020-01-07 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies for use therein |
US9572889B2 (en) | 2008-02-13 | 2017-02-21 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
US10441528B2 (en) | 2008-02-13 | 2019-10-15 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
JP2017066148A (en) * | 2009-01-30 | 2017-04-06 | ナビディア、バイオファーマスーティカルズ、インコーポレイテッドNavidea Biopharmaceuticals, Inc. | Composition for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran |
JP2015164933A (en) * | 2009-01-30 | 2015-09-17 | ナビディア、バイオファーマスーティカルズ、インコーポレイテッドNavidea Biopharmaceuticals, Inc. | Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran |
JP2012516328A (en) * | 2009-01-30 | 2012-07-19 | ネオプローブ コーポレイション | Composition for radiolabeling diethylenetriaminepentaacetic acid (DTPA) -dextran |
US10869830B2 (en) | 2009-09-28 | 2020-12-22 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
US10231923B2 (en) | 2009-09-28 | 2019-03-19 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
US10159714B2 (en) | 2011-02-16 | 2018-12-25 | Intarcia Therapeutics, Inc. | Compositions, devices and methods of use thereof for the treatment of cancers |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US10583080B2 (en) | 2014-09-30 | 2020-03-10 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US10925639B2 (en) | 2015-06-03 | 2021-02-23 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
EP3426305A4 (en) * | 2016-03-07 | 2020-01-08 | Actinium Pharmaceuticals, Inc. | Stabilized radiolabeled anti-cd45 immunoglobulin compositions |
WO2017155937A1 (en) | 2016-03-07 | 2017-09-14 | Actinium Pharmaceuticals, Inc. | Stabilized radiolabeled anti-cd45 immunoglobulin compositions |
US10501517B2 (en) | 2016-05-16 | 2019-12-10 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
US11214607B2 (en) | 2016-05-16 | 2022-01-04 | Intarcia Therapeutics Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
US11840559B2 (en) | 2016-05-16 | 2023-12-12 | I2O Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD835783S1 (en) | 2016-06-02 | 2018-12-11 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD912249S1 (en) | 2016-06-02 | 2021-03-02 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD962433S1 (en) | 2016-06-02 | 2022-08-30 | Intarcia Therapeutics, Inc. | Implant placement guide |
US10835580B2 (en) | 2017-01-03 | 2020-11-17 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
US11654183B2 (en) | 2017-01-03 | 2023-05-23 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of exenatide and co-administration of a drug |
Also Published As
Publication number | Publication date |
---|---|
AU2526497A (en) | 1997-08-22 |
CA2279349C (en) | 2007-09-25 |
WO1997028181A3 (en) | 1997-10-09 |
CA2279349A1 (en) | 1997-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2279349C (en) | Ascorbate-stabilized radiopharmaceutical method and composition | |
US6066309A (en) | Post-labeling stabilization of radiolabeled proteins and peptides | |
WO1997028181A9 (en) | Post-labeling stabilization of radiolabeled proteins and peptides | |
KR100235137B1 (en) | Monoamine diamine thiol-containing metal chelating agents | |
US5460785A (en) | Direct labeling of antibodies and other protein with metal ions | |
AU650629B2 (en) | Direct radiolabeling of antibodies and other proteins with technetium or rhenium | |
US5972308A (en) | Peptide-metal chelate conjugates | |
JP3853354B2 (en) | Stabilizers that prevent autoradiolysis of radiolabeled peptides and proteins | |
US6685912B2 (en) | Post-labeling stabilization of radiolabeled proteins and peptides | |
US5277892A (en) | In vivo lymphocyte tagging | |
KR101055700B1 (en) | Conjugates of Bifunctional Chelating Agents with Mannosyl Phosphorus Albumin and Radioisotope Labeling Compounds for Immune Cell Imaging and Detection | |
EP0772459B1 (en) | TECHNETIUM-99m LABELED IMAGING AGENTS | |
Saha | Characteristics of specific radiopharmaceuticals | |
US6551574B2 (en) | Tuftsin metallopeptide analogs and uses thereof | |
US5643549A (en) | Leukostimulatory agent for in vivo leukocyte tagging | |
AU707040B2 (en) | Monoamine, diamide, thiol-containing metal chelating agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WD | Withdrawal of designations after international publication |
Free format text: US |
|
WD | Withdrawal of designations after international publication |
Free format text: US |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/10-10/10, DRAWINGS, REPLACED BY NEW PAGES 1/13-13/13; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase in: |
Ref country code: JP Ref document number: 97527884 Format of ref document f/p: F |
|
ENP | Entry into the national phase in: |
Ref country code: CA Ref document number: 2279349 Kind code of ref document: A Format of ref document f/p: F Ref document number: 2279349 Country of ref document: CA |
|
122 | Ep: pct application non-entry in european phase |